Between April 25, 2017, and July 6, 2023, FDA identified 209 cases worldwide (197 domestic) of pruritus after stopping treatment with cetirizine (n=180), levocetirizine (n=27), or both (n=2), in the FDA Adverse Event Reporting System (FAERS) database. In all 209 cases, there was a temporal relationship between discontinuing the medicine and the onset of pruritus, and the median time to onset was 2 days, with a range of 1 to 5 days. Of these reported cases, 87 percent (n=182) were submitted by individuals using the medicines, including 6 self-identified health care professionals reporting their symptoms. In nearly 92 percent (n=97) of the 106 pruritus cases where patients reported time length of medicine usage, the length was more than 3 months, suggesting this timeframe may be a risk predictor. The median duration of medicine use before pruritus occurrence after stopping cetirizine or levocetirizine was 33 months, with a range of 1 week to 23 years. The number of pruritus cases increased with duration of use, suggesting that longer use may increase the risk of this reaction. Many reports described post-discontinuation pruritus over many areas of the body that significantly affected users’ quality of life and ability to function. Serious outcomes included disability (n=48), such as “debilitating itching to the point of being bed-ridden,” hospitalization (n=3), and thoughts of suicide or self-harm (n=2). In 92 of the 93 cases where patients reported one or more attempts at restarting then stopping the medicine, pruritus recurrence occurred. Restarting the medicine resolved pruritus in 71/79 individuals (90 percent) and tapering off the medicine after restarting it resolved symptoms in 9/24 (38 percent) of those who tried this approach.